HOMOLOGOUS IMMUNOLOGICAL STUDIES OF OCULAR LENS

Lenses of rabbits with high titers of homologous lens antibodies showed no lesions, even after repeated paracentesis of the anterior chamber in a number of such animals. In these instances, lens antibodies were shown to be present in both the primary and secondary aqueous humors. A small group of rabbits with high homologous anti-lens antibody titers were successfully bred. These had been immunized with adult rabbit lens pools in Freund's adjuvants, and had high antibody levels throughout pregnancy. No significant congenital lens lesions were found when these 18 young from 3 litters were compared with the 17 young from 3 litters of mothers who had no detectable anti-lens antibody through gestation. The latter group of does had received the equivalent doses of homologous lens in saline. Patients with cataract did not show demonstrable anti-lens antibodies in their serum when tested by the agar precipitin technic against cataractous human lens homogenates.

Download Full-text

Abstract 3712: A Randomized Placebo-Controlled Trial of a Conjugate Nicotine Vaccine (NicVAX®) in Smokers Who Want to Quit: 12 Month Results

Circulation ◽

10.1161/circ.116.suppl_16.ii_844 ◽

2007 ◽

Vol 116 (suppl_16) ◽

Author(s):

Stephen I Rennard ◽

Douglas E Jorenby ◽

David Gonzales ◽

Nancy A Rigotti ◽

Arjen de Vos ◽

...

Keyword(s):

Smoking Cessation ◽

Primary Endpoint ◽

Controlled Trial ◽

Group Analysis ◽

High Responder ◽

High Antibody ◽

Continuous Abstinence ◽

Antibody Titers ◽

Double Blinded ◽

Antibody Levels

Background: Cigarette smoking triples the risk of dying from heart disease among middle-aged men and women. A nicotine vaccine (NicVAX®) has been developed to produce nicotine-specific antibodies as a means of reducing entry of nicotine into the brain as an aid to smoking cessation. Objective: To assess 12-month safety, efficacy and immunogenicity of NicVAX in smokers who want to quit. Method: Randomized, double-blinded, placebo-controlled multicenter clinical trial with 2 dose levels of NicVAX (200μg & 400μg) and 2 schedules. Generally healthy adults who smoked ≥ 15 cigarettes/day were recruited. Subjects were randomized 2:1, active:placebo, at 9 sites in the US. The primary endpoint was self reported continuous abstinence for weeks 19 – 26 confirmed by expired CO levels of ≤ 8 ppm. Secondary endpoints include point prevalence abstinence at 12 months. Results: 301 subjects (52% female) with a mean age of 48, smoking on average 24 cigarettes/day were enrolled. A pre-defined analysis of antibody levels for subjects receiving NicVAX were reviewed and divided into low and high responder groups, with the top 30 th percentile representing the high responder group. Analysis for the primary endpoint demonstrated that 15/61 (24.6%) of subjects having the highest antibody titers achieved an 8 week period of continuous abstinence between weeks 19 –26, compared to 13/100 (13.0%) for the subjects who received placebo (p=0.04). In contrast, the quit rate for those subjects that did not achieve a high antibody titer was not significantly different from placebo (14/140, 10%). There was a significant relationship between anti-nicotine antibody levels and continuous abstinence from smoking (p=0.0001). NicVAX was well-tolerated and showed no differences in adverse events or in local/systemic reactions between placebo and each active vaccine group. Conclusion: Proof-of-concept has been established by the strong correlation of high antibody titers with smoking abstinence. Interim data (6 months post vaccination) demonstrate that generating antibodies to nicotine may be a useful approach for aiding smoking cessation. This study will be completed in Sept 2007. Immunogenicity, sustained smoking cessation and relapse rates at 12 months after vaccination will be presented.

Download Full-text

HOMOLOGOUS IMMUNOLOGICAL STUDIES OF OCULAR LENS

Journal of Experimental Medicine ◽

10.1084/jem.105.5.439 ◽

1957 ◽

Vol 105 (5) ◽

pp. 439-452 ◽

Cited By ~ 43

Author(s):

S. P. Halbert ◽

D. Locatcher-Khorazo ◽

L. Swick ◽

R. Witmer ◽

B. Seegal ◽

...

Keyword(s):

Organ Specificity ◽

Adult Rabbit ◽

Ocular Lens ◽

Cross Reactions ◽

Antigen Present ◽

Streptolysin O ◽

Rabbit Lens

Five lens antigens of rabbits can induce antibodies homologously as evidenced by agar precipitin technics. Cross-reactions of lenses of other species (organ specificity) may be due to similarity of varying numbers of these antigens. Newborn and 26-day embryo rabbit lenses seem to have decreased concentrations of, or lack, one antigen present in adult rabbit lens. Streptolysin "O" concentrates appear to act as an adjuvant for homologous lens immunization in rabbits.

Download Full-text

Direct Comparison of Antibody Responses to Four SARS-CoV-2 Vaccines in Mongolia

10.1101/2021.08.22.21262161 ◽

2021 ◽

Author(s):

Naranjargal J. Dashdorj ◽

Oliver F. Wirz ◽

Katharina Roeltgen ◽

Emily Haraguchi ◽

Anthony S. Buzzanco ◽

...

Keyword(s):

Antibody Responses ◽

Health Interventions ◽

High Antibody ◽

Antibody Testing ◽

Public Health Interventions ◽

Vaccine Responses ◽

Blocking Activity ◽

Antibody Titers ◽

Alpha Variant ◽

Antibody Levels

Different vaccines for SARS-CoV-2 are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four Covid vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant RBD proteins reveal marked differences in the vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control the COVID-19 pandemic in Mongolia and worldwide.

Download Full-text

Prevalence and Induction of Circulating Antibodies against Recombinant Staphylokinase

Thrombosis and Haemostasis ◽

10.1055/s-0038-1642396 ◽

1994 ◽

Vol 71 (01) ◽

pp. 129-133 ◽

Cited By ~ 33

Author(s):

P J Declerck ◽

S Vanderschueren ◽

J Billiet ◽

H Moreau ◽

D Collen

Keyword(s):

Intravenous Administration ◽

Human Subjects ◽

Microtiter Plates ◽

Staphylococcus Aureus Bacteremia ◽

Alternative Agent ◽

Antibody Titers ◽

Potential Alternative ◽

Circulating Antibodies ◽

Low Levels ◽

Antibody Levels

SummaryStreptokinase (SK) is a routinely used thrombolytic agent but it is immunogenic and allergenic; staphylokinase (STA) is a potential alternative agent which is under early clinical evaluation. The comparative prevalence of antibodies against recombinant STA (STAR) and against SK was studied in healthy subjects and their induction with intravenous administration in small groups of patients.Enzyme-linked immunosorbent assays, using microtiter plates coated with STAR or SK and calibration with affinospecific human antibodies, revealed 2.1 to 65 μg/ml (median 11 μg/ml) anti-STAR antibodies and 0.9 to 370 μg/ml (median 18 μg/ml) anti-SK antibodies (p <0.001 vs anti-STAR antibodies) in plasma from 100 blood donors, with corresponding values of 0.6 to 100 μg/ml (median 7.1 μg/ml) and 0.4 to 120 μg/ml (median 7.3 μg/ml), respectively, in 104 patients with angina pectoris. Three out of 17 patients with Staphylococcus aureus bacteremia had significantly increased anti-STAR antibody levels (150, 75 and 75 μg/ml), and STAR neutralizing activities (2.2, 3.6 and 4.1 μg STAR neutralized per ml plasma, respectively). In 6 patients with acute myocardial infarction, given 10 mg STAR intravenously over 30 min, median anti-STAR antibody levels were 3.5 μg/ml at baseline, 2.9 μg/ml at 6 to 8 days and 1.2 μg/ml at 2 to 9 weeks, with median corresponding titers of STAR neutralizing activity at 2 to 9 weeks of 42 μg/ml plasma. Conversely, in 5 patients treated with 1,500,000 units SK over 60 min, median anti-SK antibodies increased from 2.9 μg/ml at baseline to 360 μg/ml at 5 to 10 days, with corresponding median SK neutralizing activities of 13 μg/ml. Antibodies against STAR did not cross-react with SK and vice versa.Plasma from human subjects contains low levels of circulating antibodies against recombinant staphylokinase, and intravenous administration of this compound boosts antibody titers. These antibodies do however not cross-react with streptokinase, whereby the use of these two immunogenic thrombolytic agents would not be mutually exclusive.

Download Full-text

Management of Haemophilia A with Antibodies - The Effect of Combined Treatment with Factor VIII, Hydrocortisone and Cyclophosphamide

Thrombosis and Haemostasis ◽

10.1055/s-0038-1660131 ◽

1985 ◽

Vol 54 (04) ◽

pp. 776-779 ◽

Cited By ~ 13

Author(s):

U Hedner ◽

L Tengborn

Keyword(s):

Factor Viii ◽

Combined Treatment ◽

Factor Ix ◽

Treatment Schedule ◽

High Antibody ◽

Anamnestic Response ◽

Short Intervals ◽

Low Responders ◽

Antibody Levels ◽

High Responders

SummaryImmune tolerance has by several methods been induced in haemophiliacs with antibodies. A conversion of “high responders” into “low responders” was previously reported after repeated moderate factor IX doses over periods of 7-10 days in combination with cyclophosphamide and steroids in two patients with haemophilia B and inhibitors. This paper reports similar results in a heamophilia A patient by giving factor VIII, cyclophosphamide, and steroids during relatively short periods of time (7-8 days). The anamnestic response markedly decreased already following the first treatment and never exceeded a level of 1 u/ml (˜ 3 BU/ml) even when boosted with ordinary factor VIII doses for only 3 days. It is concluded that the markedly decreased secondary antibody response is most probably the result of factor VIII given at short intervals (twice a day) for periods of up to about one week when given in combination with cyclophosphamide and steroids. The same effect may be achieved by other methods. The treatment schedule suggested in the present paper is, however, simple and avoids long periods of high antibody levels. Furthermore, the total factor VIII dose used is lower than suggested in most other treatment schedules, which makes the treatment substantially less expensive.

Download Full-text

POLIOMYELITIS IN CANADIAN ESKIMOS: LABORATORY STUDIES. V. TYPE 1 AND TYPE 3 POLIOMYELITIS ANTIBODY LEVELS IN BAFFIN ISLAND ESKIMOS

Canadian Journal of Biochemistry and Physiology ◽

10.1139/y54-013 ◽

1954 ◽

Vol 32 (1) ◽

pp. 119-125

Author(s):

W. Wood ◽

Eina M. Clark ◽

F. T. Shimada ◽

A. J. Rhodes

Keyword(s):

Medical Records ◽

Baffin Island ◽

Tissue Cultures ◽

Laboratory Studies ◽

Poliomyelitis Virus ◽

Antibody Titers ◽

Antibody Levels ◽

Type 3

Studies on the basic immunology of poliomyelitis in Canadian Eskimos have been continued. Some 87 sera collected from Eskimos at Pangnirtung, Baffin Island, have been examined for the presence of Type 1 and Type 3 poliomyelitis antibody by quantitative tests in tissue cultures. The same sera were previously examined for Type 2 antibody by quantitative tests in mice. The results of the three determinations are now presented together for comparison. These sera came from Eskimos aged 2 to 72 years of age. None of the Eskimos showed any evidence of paralysis. Examination of the medical records did not suggest that any paralytic disease had been present in this part of Baffin Island. Very few of the sera showed the presence of poliomyelitis antibody; thus, Type 1 antibody was demonstrated in the sera of 8%, Type 2 antibody in the sera of 9%, and Type 3 antibody in the sera of 14%. No significant number of Eskimos below the age of 45 years had acquired poliomyelitis antibody. The antibody titers mostly ranged between 10−1.0 and 10−2.0, and were significantly lower than the titers customarily found in recently paralyzed cases. These findings suggest that poliomyelitis infection occurred in Pangnirtung Eskimos many years before the date on which the samples were taken (1951). These results point to the worldwide prevalence of the three types of poliomyelitis virus.

Download Full-text

Seasonality of month of birth of patients with Graves’ and Hashimoto’s diseases differ from that in the general population

Acta Endocrinologica ◽

10.1530/eje-07-0015 ◽

2007 ◽

Vol 156 (6) ◽

pp. 631-636 ◽

Cited By ~ 28

Author(s):

Gerasimos E Krassas ◽

Konstantinos Tziomalos ◽

Nikolaos Pontikides ◽

Hadas Lewy ◽

Zvi Laron

Keyword(s):

General Population ◽

Perinatal Period ◽

Thyroid Peroxidase ◽

Month Of Birth ◽

Autoimmune Thyroid ◽

Common Etiology ◽

Antibody Titers ◽

Low Levels ◽

Antibody Levels

Objective: We aimed to test the viral hypothesis in the pathogenesis of autoimmune thyroid disease (AITD). Design: We determined the pattern of month of birth (MOB) distribution in patients with AITD and in the general population and searched for differences between them. Methods: A total of 1023 patients were included in this study; 359 patients had Graves’ hyperthyroidism (GrH) and 664 had Hashimoto’s hypothyroidism (HH). We divided the patients with HH into three subgroups according to their thyroid peroxidase (TPO) antibody titers at diagnosis: low levels (<500 IU/ml), high levels (500–1000 IU/ml), and extremely high levels (>1000 IU/ml). We used cosinor analysis to analyze the data. Results: Overall, patients with GrH and HH had a different pattern of MOB distribution when compared with the general population and between groups. Furthermore, among both patients with GrH and HH, both genders had a different pattern of MOB distribution when compared with the general population and this pattern was also different between genders. Finally, only women with extremely high titers of TPO antibodies at diagnosis and men with low or extremely high TPO antibody levels showed rhythmicity in MOB, with a pattern of MOB distribution different from that in controls. Conclusions: The different MOB seasonality in both GrH and HH points towards a similar maybe even common etiology with type 1 diabetes mellitus and multiple sclerosis, namely a seasonal viral infection as the initial trigger in the perinatal period, the clinical disease resulting from further specific damage over time.

Download Full-text

Serological Evaluation of Specific-Antibody Levels in Patients Treated for Chronic Chagas' Disease

Clinical and Vaccine Immunology ◽

10.1128/cvi.00106-07 ◽

2007 ◽

Vol 15 (2) ◽

pp. 297-302 ◽

Cited By ~ 38

Author(s):

Olga Sánchez Negrette ◽

Fernando J. Sánchez Valdéz ◽

Carlos D. Lacunza ◽

María Fernanda García Bustos ◽

María Celia Mora ◽

...

Keyword(s):

Chagas Disease ◽

Treatment Effectiveness ◽

Enzyme Linked Immunosorbent Assay ◽

Serum Samples ◽

Serological Tests ◽

Recombinant Antigens ◽

Antibody Titers ◽

Laboratory Procedures ◽

The Individual ◽

Antibody Levels

ABSTRACT Serological tests are the main laboratory procedures used for diagnosis during the indeterminate and chronic stages of Chagas' disease. A serological regression to negativity is the main criterion used to define parasitological cure in treated patients. The aim of this work was to monitor the individual specificities of antibody levels for 3 years posttreatment in 18 adult patients. Conventional serological techniques (hemagglutination assays and enzyme-linked immunosorbent assay [ELISA]) were modified by using recombinant antigens to detect early markers of treatment effectiveness. For this purpose, serum samples were taken before and during treatment and every 6 months after treatment for at least 3 years. When hemagglutination assays were used, a decrease in antibody levels was observed in only one patient. When ELISA with serum dilutions was used, antibody clearance became much more apparent: in 77.7% (14/18) of the patients, antibody titers became negative with time. This was observed at serum dilutions of 1/320 and occurred between the 6th and the 30th months posttreatment. The immune response and the interval for a serological regression to negativity were different for each patient. For some of the recombinant antigens, only 50% (9/18) of the patients reached the serological regression to negativity. Recombinant antigen 13 might be a good marker of treatment effectiveness, since 66.6% (six of nine) of the patients presented with an early regression to negativity for specific antibodies to this antigen (P = 0.002).

Download Full-text

Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases

The Journal of Rheumatology ◽

10.3899/jrheum.150397 ◽

2016 ◽

Vol 43 (2) ◽

pp. 267-272 ◽

Cited By ~ 14

Author(s):

Adi Broyde ◽

Uri Arad ◽

Noa Madar-Balakirski ◽

Daphna Paran ◽

Ilana Kaufman ◽

...

Keyword(s):

Humoral Response ◽

Polysaccharide Vaccine ◽

Inflammatory Rheumatic Diseases ◽

Technical Problems ◽

Tnf Α ◽

Antibody Titers ◽

Inflammatory Bowel ◽

Factor Α ◽

Antibody Levels ◽

Necrosis Factor

Objective.To estimate the longterm humoral response of an antipneumococcal polysaccharide vaccine (PPSV23) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or inflammatory bowel disease (IBD)-associated spondyloarthropathy (SpA), and the effect of demographic and clinical factors and treatment on the longterm efficacy of the vaccine.Methods.A total of 145 consecutive patients treated with biologics [tumor necrosis factor-α (TNF-α) or interleukin 6 (IL-6) receptor inhibitors] or methotrexate (MTX) participated in this study. Fifteen were excluded because of absent information regarding their vaccination status (n = 9) or because of technical problems in obtaining their serum sample (n = 6). They were diagnosed with RA (n = 63, 48.5%), PsA (n = 29, 22.3%), AS (n = 28, 21.5%), or IBD-associated SpA (n = 3, 2.3%). Their mean age was 54.6 years, and 61.5% were women. Data were collected on the timing of vaccination, demographic and clinical characteristics, and treatment, and patients’ serum antipneumococcal antibody levels were tested.Results.Two-thirds of the patients (67.7%) had received PPSV23 45 months (mean) earlier. Treatment included TNF-α inhibitors (73.9%), IL-6 receptor inhibitors (13.1%), or MTX without a biological treatment (13%). The uptake of vaccination was significantly higher in the older population (> 65 yrs). Vaccinated patients had significantly higher antibody levels compared with vaccine-naive patients. The antibody levels had been preserved after 10 years. MTX use, but not biologics, was associated with significantly lower antibody levels.Conclusion.The longterm efficacy of the PPSV23 vaccination seems to be preserved among patients with RA, PsA, AS, and IBD-associated SpA for at least 10 years. Efficacy is slightly impaired by MTX, but it is not affected by biologics. These findings suggest that revaccination after 5 years might not be needed for all, and testing the antibody titers should be considered to identify those who may benefit from revaccination.

Download Full-text

PASSIVE IMMUNIZATION

PEDIATRICS ◽

10.1542/peds.32.4.599 ◽

1963 ◽

Vol 32 (4) ◽

pp. 599-609

Author(s):

Geoffrey Edsall

Keyword(s):

Diphtheria Toxin ◽

Gamma Globulin ◽

Passive Immunization ◽

Gas Gangrene ◽

High Antibody ◽

Antibody Titers ◽

The Subject ◽

Guiding Principles ◽

Routine Procedures ◽

The Ideal

Passive immunization has existed for over 70 years, ever since Von Behring and Kitasato demonstrated its effectiveness in neutralizing diphtheria toxin. In fact, at first glance one might think that there was little new to say on this subject. However, the very fact that its concepts and practices have been so long accepted and–in the minds of many–have fallen into the pattern of purely routine procedures, is in itself sufficient justification to re-examine the subject. In addition, moreover, there have been a number of changes in the range of diseases for which passive immunization may be employed, the type of antiserum used, and the guiding principles for use of such preparations. Therefore, it may be timely to deal with some of the present considerations that apply to passive immunization, its prospects, its scope, and its limitations. At the risk of repeating old and familiar cliches it appears desirable to summarize, at first, the guiding principles which apply to the effectiveness (or ineffectiveness) of passive immunization. First of all, it is well established that some techniques of passive immunization are highly effective–e.g., diphtheria prophylaxis with antitoxin; some are very useful but fall short of the ideal of routine success with the purpose intended–e.g., the use of gamma-globulin for the modification of measles; whereas others are of relatively uncertain value so that their usefulness in medical practice still continues to be debated–e.g., gas gangrene antitoxin. The reasons for such great disparity in the efficacy of different antisera cannot easily be put into generalizations, but surely the varied pathogenesis of the diseases in question must be a major factor, as well as the fact that high antibody titers can readily be obtained for some such sera, whereas they are difficult or impossible to achieve with others.

Download Full-text